Gilvetmab is the first and only immune checkpoint inhibitor developed for the treatment of mast cell tumors (MCTs) and melanomas in dogs.
LEARN MORETriple-action, once-a-day treatment for 7 days for even the most stubborn cases associated with susceptible strains of yeast and bacteria in canines.
LEARN MORE